Skip to main content
Ir a la página de inicio de la Comisión Europea (se abrirá en una nueva ventana)
español es
CORDIS - Resultados de investigaciones de la UE
CORDIS

A BREAKTHROUGH TECHNOLOGY DESIGNED TO PRESERVE SIGHT AND HALTING VISION LOSS ASSOCIATED WITH A RANGE OF RETINAL DISEASE BY PREVENTING THE DEATH OF KEY RETINAL CELLS .

Descripción del proyecto

El futuro parece más prometedor para el tratamiento de organopatías

Millones de personas en todo el mundo padecen organopatías graves, como insuficiencia hepática aguda y retinopatías, con tratamientos eficaces limitados. Estas afecciones suelen provocar daños irreversibles y son potencialmente mortales. A pesar de los avances médicos, prevenir la muerte celular y preservar la función de los órganos siguen siendo retos importantes en el tratamiento. Teniendo esto en cuenta, el objetivo del proyecto SeaBeEYE, financiado con fondos europeos, es desarrollar fármacos innovadores diseñados para frenar las rutas de muerte celular y preservar la pérdida de visión en pacientes que padecen retinopatías degenerativas. Esta iniciativa se centra en hacer frente a las retinopatías con fármacos innovadores. Tras los prometedores resultados «in vivo», los fármacos están ya listos para los ensayos clínicos. Ello constituye un paso importante en el desarrollo preclínico para las enfermedades oculares.

Objetivo

I am the CEO and Cofounder of SeaBeLife, a French biotechnology company developing First-In-Class drugs to treat severe pathologies affecting our vital organs for which there are no effective treatments. We develop an innovative therapeutic approach protected by 4 patents and with a lead program to treat Acute Liver Failure and a second program to preserve sight and halting vision loss associated with a range of retinal disease by preventing the death of key retinal cells. We are developing a first-in-class drug based on a dual-targeted approach, capable of stopping directly and simultaneously two forms of regulated cell death pathways known to be involved in triggering of numerous acute and chronic pathologies and contributing to organ damage. Our molecule protects the cells, prevents tissue damage, and finally preserves and restores organ function. SeaBeLife is the only company worldwide developing such a therapeutic approach. Our molecule has a direct protective effect on cells and has the potential to prevent evolution to severe life-threatening form. We have already obtained very convincing in vivo results in several highly predictive models. Our molecules were tested on pharmacologically relevant murine models and have shown no toxicity and strong efficacy. SeaBeLife is composed of an experienced and complementary operational team managing by two women and supported by a scientific and strategic advisory board with scientific and medical experts of extensive expertise in drug development. We have already raised 4.3M€ to develop our technology and we are ready to bring our molecules to the clinic and validate its safety and efficacy. The main milestones over the next 2 years will be the production of compliant clinical batches and the realization of phase 1 and phase 2a clinical trials. The WomenTechEU award and funding will allow us to gain visibility as women entrepreneurs and also to take an important step in our pre-clinical development for eye diseases.

Ámbito científico (EuroSciVoc)

Palabras clave

Programa(s)

Tema(s)

Régimen de financiación

HORIZON-CSA - HORIZON Coordination and Support Actions

Ver todos los proyectos financiados en el marco de este régimen de financiación

Convocatoria de propuestas

(se abrirá en una nueva ventana) HORIZON-EIE-2022-SCALEUP-02

Ver todos los proyectos financiados en el marco de esta convocatoria

Coordinador

SEABELIFE SAS
Aportación neta de la UEn
€ 75 000,00
Dirección
PLACE GEORGES TEISSIER, STATION BIOLOGIQUE DE ROSCOFF
29680 Roscoff
Francia
Región
Bretagne Bretagne Finistère
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Enlaces
Coste total
Sin datos